Cell MedX Corp. (CMXC) Enters Into an Option Agreement With Its President and...
HENDERSON, NV--(Marketwired - Aug 11, 2015) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company"), a development stage company focused on the discovery, development and commercialization of...
View ArticleMELA Sciences, Inc., A Leader In The Fight Against Melanoma, Hosts Symposium...
My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about MELA Download image MELA Sciences. (PRNewsFoto/MELA Sciences, Inc.)...
View ArticleCell MedX Corp. (CMXC) Mobilizes Efforts to Commence Clinical Trials
Company Study Aims to Determine Efficacy of Diabetes Treatment LAS VEGAS, NV--(Marketwired - Jul 7, 2015) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company") is pleased to announce that...
View ArticleMELA Sciences Participates in the American Society of Dermatologic Surgery...
(Source: MELA Sciences Inc) IRVINGTON, N.Y., October 2, 2013 - MELA Sciences, Inc. (NASDAQ: MELA), the medical device company that developed and is commercializing MelaFind®, the first and only...
View ArticleMELA Sciences Initiates First Study to Investigate Real-World Clinical Impact...
IRVINGTON, N.Y., June 3, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the United States and the...
View ArticleMELA Sciences Reports Positive Reception for its Optical Melanoma Diagnostic...
(Source: MELA Sciences Inc) MELA Sciences Reports Positive Reception for its Optical Melanoma Diagnostic Device at Clinical Advisory Meeting and Mount Sinai Winter Dermatology Symposium New York, NY...
View ArticleMELA Sciences, Inc. to Participate in the Fall Clinical Dermatology...
(Source: MELA Sciences Inc) Leading Dermatologists to Present Clinical Findings in Four Poster Presentations at the 32nd Annual Fall Clinical Dermatology Conference in Las Vegas, Nevada IRVINGTON,...
View ArticleMELA Sciences, Inc., a Leader in the Fight Against Melanoma, Participates in...
My news for Investors AtLeast one of the check box should be selected You are following news about Follow the latest news about MELA Download image MELA Sciences. (PRNewsFoto/MELA Sciences, Inc.)...
View ArticleMELA Sciences Reports Third Quarter 2014 Financial Results
Conference Call Today at 4:30 p.m. Eastern Time IRVINGTON, N.Y., Nov. 12, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, a non-invasive software-driven...
View ArticleMelanoma Diagnostics Leader, MELA Sciences, Hosts Clinical Advisory Meeting...
(Source: MELA Sciences Inc) New York, NY & Irvington, NY December 5, 2013 - MELA Sciences, Inc. (NASDAQ: MELA) designer and developer of MelaFind®, an FDA approved non-invasive optical device that...
View ArticleMELA Sciences, Inc. to Participate in the Fall Clinical Dermatology Conference
IRVINGTON, N.Y., Oct. 16, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), the medical device company that has developed and is commercializing MelaFind®, the first and only FDA approved...
View ArticleCell MedX Corp. (CMXC) Advances Development Timeline
LAS VEGAS, NV--(Marketwired - Jul 20, 2015) - Cell MedX Corp. (OTCQB: CMXC) ("Cell MedX" or the "Company") an early development stage company focused on the discovery, development and commercialization...
View ArticleMELA Sciences Reports Positive Reception for its Optical Melanoma Diagnostic...
MELA Sciences, Inc. (NASDAQ: MELA) designer and developer of MelaFind®, an FDA approved non-invasive optical device that assists dermatologists in the diagnosis of melanoma, received positive...
View ArticleMELA Sciences Reports Positive Reception for its Optical Melanoma Diagnostic...
NEW YORK & IRVINGTON, N.Y.--(BUSINESS WIRE)--MELA Sciences, Inc. (NASDAQ: MELA) designer and developer of MelaFind®, an FDA approved non-invasive optical device that assists dermatologists in the...
View ArticleDermatologist Highlights Medical Benefits of MelaFind Device in Aiding...
MAUI, Hawaii & IRVINGTON, N.Y.--(BUSINESS WIRE)--MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis...
View ArticleMelanoma Diagnostics Leader, MELA Sciences, Hosts Clinical Advisory Meeting...
MELA Sciences, Inc. (NASDAQ:MELA) designer and developer of MelaFind®, an FDA approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage,...
View ArticleMELA Sciences Announces New Study Results Demonstrating Improved Diagnostic...
IRVINGTON, N.Y., July 24, 2014 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, an optical diagnostic device approved for use in the U.S. and the European Union...
View ArticleMelanoma Diagnostics Leader, MELA Sciences, Hosts Clinical Advisory Meeting...
NEW YORK & IRVINGTON, N.Y.--(BUSINESS WIRE)--MELA Sciences, Inc. (NASDAQ:MELA) designer and developer of MelaFind®, an FDA approved non-invasive optical device that assists dermatologists in...
View ArticleNew Data Presented at the Fall Clinical Dermatology Conference Supports...
(Source: MELA Sciences Inc) IRVINGTON, N.Y., Oct. 21, 2013 (GLOBE NEWSWIRE) - MELA Sciences, Inc. (MELA), a leader in the fight against melanoma with MelaFind®, the first and only FDA approved optical...
View ArticleVerisante Technology, Inc. Welcomes Dr. Kenneth Beer and Dr. Philip Werschler...
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jul 29, 2014) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, is pleased...
View Article